BriaCell Therapeutics Corp (BCT) NPV
BriaCell Therapeutics Corp. is a clinical stage immunotherapy company. The Company is focused on developing treatments that boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors. Its lead drug candidate, Bria-IMT, is a targeted immunotherapy being developed for the treatment of advanced breast cancer. The Company is focused on conducting Phase I/IIa clinical trial of Bria-IMT in a combination study with immune checkpoint inhibitors such as the Incyte drugs retifanlimab, an anti-PD-1 antibody similar to pembrolizumab, and epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). The Company is also focused on development of Bria-OTS, which is an off-the-shelf personalized immunotherapy based on a patient’s HLA-type. Its other pre- clinical candidates include Bria-Pros, Bria-Lung, Bria-Mel, Bria-TILsRx and others.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.